Abstract:Yongkun Du, Shuai Wang, Ting Zhou, Zhongyan Zhao Department of Critical Care Medicine, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, 130033, People's Republic of China Correspondence: Zhongyan Zhao, Email Background: Recent evidence suggests that the gut microbiome and metabolites are intricately involved in Chronic Obstructive Pulmonary Disease (COPD) pathogenesis, yet the precise causal relationships remain unclear due to confounding factors and reverse causation. This study employs bidirectional two-sample Mendelian Randomization (MR) to clarify these connections. Methods: Summary data from publicly available Genome-Wide Association Studies (GWAS) concerning the gut microbiome, metabolites, and COPD were compiled. The selection of genetic instrumental variables (Single Nucleotide Polymorphisms, or SNPs) for MR analysis was conducted meticulously, primarily utilizing the Inverse Variance Weighting (IVW) method, supplemented by MR-Egger regression and the Weighted Median (WM) approach. The evaluation of heterogeneity and horizontal pleiotropy was performed using Cochran's Q test, the MR-Egger intercept test, and the MR-PRESSO global test. Sensitivity analyses, including leave-one-out tests, were conducted to verify the robustness of our results. And the mediation effect of gut microbiota-mediated changes in metabolites on the causal relationship with COPD was analyzed. Results: Our study identified nine significant gut microbiota taxa and thirteen known metabolites implicated in COPD pathogenesis. Moreover, associations between the onset of COPD and the abundance of five bacterial taxa, as well as the concentration of three known metabolites, were established. These findings consistently withstood sensitivity analyses, reinforcing their credibility. Additionally, our results revealed that gut microbiota contribute to the development of COPD by mediating changes in metabolites. Conclusion: Our bidirectional Two-Sample Mendelian Randomization analysis has revealed reciprocal causal relationships between the abundance of gut microbiota and metabolite concentrations in the context of COPD. This research holds promise for identifying biomarkers for early COPD diagnosis and monitoring disease progression, thereby opening new pathways for prevention and treatment. Further investigation into the underlying mechanisms is essential to improve our understanding of COPD onset. Keywords: chronic obstructive pulmonary disease, gut microbiota, metabolites, Mendelian randomization, causal effect Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung disorder characterized by chronic respiratory symptoms such as dyspnea, cough, sputum production, and/or exacerbations. These symptoms result from abnormalities in the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema), leading to persistent and typically progressive airflow obstruction. 1 This disease ranks as the fourth leading cause of mortality globally, claiming the lives of over three million patients annually. 2 The multifaceted nature of COPD underscores its impact, representing a substantial economic and clinical burden. 3,4 The intricate interplay within the gut microbiome, which comprises an intricate assembly housing over 1000 microbial entities within the digestive tracts of humans and animals, 5 orchestrates a complex impact on diseases spanning multiple bodily systems. A disruption in this intricate microbial community can induce alterations in pulmonary bacterial composition, giving rise to the "Gut-Lung axis". 6 This phenomenon enables the entry of microbial metabolites into the bloodstream, establishing a linkage between gut and lung, thereby fomenting inflammation at both local and systemic levels. The sustained nature of this inflammatory response may precipitate subacute or chronic manifestations. 7 Importantly, a growing body of research highlights that the changes in gut microbiota and metabolites play an important role in the pathogenesis of COPD. 8,9 By comparing the gut microbiome and metabolomic profiles of twenty-eight COPD patients and twenty-nine healthy individuals, Bowerman et al 10 identified one hundred and forty-six bacterial species that differed between the two groups, six types of gut bacteria were found to be enriched in individuals with COPD at the bacterial family level, and sixteen metabolites from lipids, amino acids, or foreign sources that were considered significantly different. Although the association between gut microbiota and COPD risk is well-documented, clarifying the causation of these associations remains a challenge. Mendelian randomization (MR) represents a critical statistical approach for discerning c -Abstract Truncated-

Association of the gut microbiome and different phenotypes of COPD and asthma: a bidirectional Mendelian randomization study

Genetic evidence on the causality between gut microbiota and various asthma phenotypes: a two-sample Mendelian randomization study

Assessing causal relationships between gut microbiota and asthma: evidence from two sample Mendelian randomization analysis

Causal Relationship Between Gut Microbiota and Chronic Obstructive Pulmonary Disease: A Bidirectional Two-Sample Mendelian Randomization Study

The associations between gut microbiota and chronic respiratory diseases: a Mendelian randomization study

Gut microbiota and chronic obstructive pulmonary disease: a Mendelian randomization study

Unveiling genetic links between gut microbiota and asthma: a Mendelian randomization

Genetic evidence of bidirectional mendelian randomization study on the causality between gut microbiome and respiratory diseases contributes to gut-lung axis

Genetic Insights into the Gut-Lung Axis: Mendelian Randomization Analysis on Gut Microbiota, Lung Function, and COPD

Causal Effects of Gut Microbiota and Metabolites on Chronic Obstructive Pulmonary Disease: A Bidirectional Two Sample Mendelian Randomization Study

Mendelian randomization analysis identifies intestinal flora causally associated with asthma-related infections and pneumonia

Genetic association and bidirectional Mendelian randomization for causality between gut microbiota and six lung diseases

Causal effects between gut microbiota and pulmonary arterial hypertension: A bidirectional Mendelian randomization study

Gut microbiota and risk of lower respiratory tract infections: a bidirectional two-sample Mendelian randomization study

Genetic liability of gut microbiota for idiopathic pulmonary fibrosis and lung function: a two-sample Mendelian randomization study

Investigating causal relationships between the gut microbiota and allergic diseases: A mendelian randomization study

P1.10-03 Gut Microbiota and Lung Cancer: A Mendelian Randomisation Study

Associations between gut microbiota and chronic sinusitis: A bidirectional Mendelian randomization study

Association of Asthma and Bronchiectasis: Mendelian Randomization Analyses and Observational Study

Common gastrointestinal diseases and chronic obstructive pulmonary disease risk: a bidirectional Mendelian randomization analysis

A Bidirectional Mendelian Randomization reveals the association between the abundance of Gut Microbiota and multiple subtypes of Lung Cancer